WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
CNS Pharmaceuticals, Inc. (CNSP)
Company Research
Source: GlobeNewswire
VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its development partner CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS”), announce that ImQuest Biosciences has been engaged to expand in vitro and in vivo testing of WP1122, a drug candidate for the treatment of COVID-19. The agreement with ImQuest Biosciences was entered into by WPD’s license partner Moleculin Biotech, Inc. (NASDAQ: MBRX) (“Moleculin”), to expand testing of WP1122 as a potential treatment for the Coronavirus. WPD is not making any express or implied claims that this new partnership may eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. ImQuest BioSciences is a preclinical CRO that provides expert services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory d
Show less
Read more
Impact Snapshot
Event Time:
CNSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNSP alerts
High impacting CNS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CNSP
News
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.MarketBeat
- CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024Accesswire
- CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyAccesswire
CNSP
Sec Filings
- 1/3/25 - Form 8-K
- 12/11/24 - Form 8-K
- 12/3/24 - Form 8-K
- CNSP's page on the SEC website